Olaparib to treat non-BRCA breast cancer
2012
Kawasaki Medical School, Kurashiki, Japan
BRCA is a risk genetic marker of developing familial breast cancer. There are some therapeutic agents that have been shown to be effective against this type of cancer, like olaparib. However, there is little information about their anti-tumour activity in non-BRCA sporadic breast cancer. Here, several human cell lines derived from patients with sporadic breast cancer were used to test the effects of olaparib, alone or in combination with other chemotherapeutic agents, on different cancer-related features in these cells. The results show that olaparib inhibited the growth of different types of breast cancer cells through cell cycle arrest and induction of apoptosis but was ineffective in two HER+ breast cancer cell lines. However, in all cell lines, there was a significant decrease in the proportion of cancer stem cells. Olaparib also increased the expression of p-EKR, and its inhibition could counteract the effect of olaparib. Only one of the chemotherapeutic agents tested together with olaparib seemed to have additive anti-tumour activity and it further increased the observed effects of olaparib alone. In this study, the researchers demonstrate the anti-tumour activity of olaparib in non-BRCA human breast cancer cells and partially elucidate its mechanisms of action. They also describe a potential combinatory therapeutic strategy that could be used to treat non-BRCA sporadic breast cancer.
Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells
Junichi Kurebayashi
Added on: 10-19-2021
[1] https://link.springer.com/article/10.1007%2Fs12282-012-0356-z[2] https://data.jrc.ec.europa.eu/dataset/ffebe454-ed9a-47cf-8a33-8cf70c1b7d38
